Active Biotech doses first patient in amended tasquinimod myelofibrosis trial

Reuters2026/07/24 06:38

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Active Biotech reported the first patient dosed in the amended Phase Ib/II HO172 tasquinimod trial in myelofibrosis.
Protocol changes increase dosing flexibility, aiming to improve patient management and trial execution.
Study targets patients refractory to, or ineligible for, JAK2 inhibitors; tasquinimod is evaluated as monotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Active Biotech AB published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Active Biotech doses first patient in amended tasquinimod myelofibrosis trial

You may also like

Crypto prices